Lower respiratory diseases including chronic obstructive pulmonary disease (COPD) were the sixth leading cause of death in the U.S. in 2022, accounting for 4.5% of all deaths registered that year. That’s according to a report, “Deaths: Leading Causes for 2022,” released by the U.S. Centers for Disease Control and…

Respinova’s new airway device, called Pulsehaler, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). That means it can be marketed as a safe and effective medical device to ease breathing in people with airway restrictions, such as chronic obstructive pulmonary disease (COPD). “We…

Use of electronic cigarettes (e-cigarettes) is associated with an increased risk of respiratory diseases, including chronic obstructive pulmonary disease (COPD), among young adults, irrespective of other tobacco product use, a large U.S.-based study shows. Compared to healthy people, those currently using e-cigarettes, commonly called vaping, had a 43% increased…

Shirts with smart technology could be used in place of traditional laboratory equipment to measure lung function, and prove to be particularly useful in respiratory conditions such as asthma, cystic fibrosis, or chronic obstructive pulmonary disease (COPD), new research suggests. The data were discussed in a presentation, titled…

The lung therapy developer Pulmatrix has obtained global rights to RespiVert’s respiratory-disease treatments under a licensing arrangement. Under the deal, Pulmatrix gained access to the kinase inhibitors that RespiVert has developed for lung conditions such as chronic obstructive pulmonary disease (COPD). Pumatrix also develops kinase inhibitors. RespiVert is a subsidiary of Janssen…

HealthFactors and Koronis Biomedical Technologies are partnering on developing equipment to help people with respiratory conditions associated with chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The collaboration is aimed at creating smart inhaler devices that are so effective and easy to use that they become part of mainstream…

International Biophysics Corporation announced a revenue growth of 34% in 2016 due to a 53% increase in unit sales of the AffloVest and other surgical product lines in the United States. AffloVest is a lung clearance therapy for patients with respiratory diseases such as chronic obstructive pulmonary disease (COPD). “As we enter our…

Boehringer Ingelheim is partnering with Weill Cornell Medicine to discover new treatment approaches to potentially halt or reverse the progression of chronic obstructive pulmonary disease (COPD). The three-year cooperative agreement will combine the research of Weill Cornell Medicine’s Department of Genetic Medicine in novel therapeutic concepts for airway repair…

The University of Newcastle (UON) in Australia was awarded a total of $10.8 million from the National Health and Medical Research Council (NHMRC) to support 14 projects and one Career Development Fellowship. Of the total, $3.4 million will be dedicated to help develop new treatments for asthma and chronic obstructive…